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Background
With the development of transcriptome and genome sequencing technologies, many long noncoding RNAs (lncRNAs) have been detected and reported, [1, 2] and found involved in almost all aspects of gene expression including protein translation and stability. [3] These lncRNAs have shown aberrant expression in tumor tissues and patient serum. Abundant evidence has shown lncRNAs involved in many cellular cancer pathways, including the regulation of gene expression, protein localization, and formation of essential protein complex substructures [4] [5] [6] . Furthermore, lncRNAs such as MALAT1, HOTAIR, and H19 ere found to act as tumor suppressor genes or oncogenes in cancer development [7] [8] [9] .
Recently, a novel lncRNA, highly upregulated in liver cancer (HULC), has attracted widespread attention. HULC has been found dysregulated in various human tumors, such as hepatocellular carcinoma, colorectal carcinoma, osteosarcoma, gastric cancer, and diffuse large Bcell lymphoma [10] [11] [12] [13] . Abnormal expression of HULC in cancerous tissue or serum has confirmed it as an important player in tumorigenesis of cancers. A high level of HULC was found associated with metastasis and prognosis of cancers [10] [11] [12] [13] . HULC might be a diagnostic biomarker and prognostic factor of cancers. However, the effect of HULC on cancer prognosis is controversial, and no meta-analysis has investigated the relationship between HULC expression and prognosis.
The present meta-analysis aimed to explore the association of HULC level and clinical outcome of cancer patients to further determine the biomarker role of HULC in metastasis and prognosis of cancers.
Material and methods

Literature search strategy
Reports of studies in English or Chinese on the role of HULC in the development of human cancer were searched in PubMed, EMBASE, the Cochrane Library, China National Knowledge Infrastructure, and Wanfang databases with the key words ("hepatocellular carcinoma up-regulated long non-coding RNA" or "HULC" or "HCCAT1" or "LINC00078" or "NCRNA00078"). The last search date was September 7, 2016. References of retrieved papers and conference reports were also searched to identify relevant studies. The preferred reporting items for systematic reviews and meta-analyses (PRISMA) was listed in S1 Table.
Selection criteria
After duplicates were removed, titles and abstracts of articles were checked by 4 authors (JL, YL, JP, and YC). The full text of eligible articles was retrieved. Eligible articles had the following criteria: 1) the expression of HULC was analyzed by metastasis or survival time, 2) patients were divided by high and low expression of HULC, 3) the effects for metastasis or survival were provided or could be calculated from the available data; for the metastasis, odd ratios (ORs) of lymph node metastasis [LNM] The quality of each eligible study was assessed by the Newcastle-Ottawa Scale (NOS), consisting of selection, outcome and comparability, with scores from 0 to 9. A study with NOS score !6 was considered at high quality. Consensus in extraction was resolved by discussion and with 2 other investigators (JC, DH) if needed.
Statistical methods
This meta-analysis involved use of Review Manager 5.3 (Cochrane network). Inconsistency (I
) and Q tests (chi-square test) were used to test for heterogeneity among eligible studies. If statistical heterogeneity was found (P Q <0.05, I 2 >50%), a random-effects model based on the work of Der Simonian and laird was used to estimate the pooled OR and HR. Otherwise, a fixed-effects model according to the Mantel-Haensed method was used [14] . HRs and 95% CIs for OS were extracted from Kaplan-Meier curve analysis by using Engauge Digitizer 4.1 [15] because HRs and 95% CIs were not provided directly in some studies. Moreover, Begg's and Egger's tests were used to assess publication bias, and trim and fill analysis was used to adjust the pooled effects obtained by STATA 14.0 [16] . All tests were two-sided and P<0.05 was considered statistically significant.
Results
Characteristics of eligible studies
The literature search resulted in 9 studies eligible for the meta-analysis [11, 17-21, 13, 22, 23] (Fig 1) , 7 from China and 2 from Brazil and Korea. The studies involved a total of 966 cancer patients, with mean sample size of 107.3 patients (range 33 to 240). Six different types of cancer were evaluated: hepatocellular carcinoma, osteosarcoma and gastric cancer (n = 2 each), diffuse large B-cell lymphoma, pancreatic cancer, and colorectal carcinoma (n = 1 each). The level of HULC was detected in tumor tissue or serum by RT-PCR and the negative control was adjacent noncancerous tissues, healthy tissues, and healthy serum. Furthermore, the group cut-off value for clinic outcome determined by the original research depended on the median/ mean value of HULC level or ROC analysis. The main characteristics of each study are summarized in Table 1 and NOS scores indicate good methodological quality of the component studies with range of 7 to 8 ( Table 2) .
Association between HULC and metastasis
Association between HULC and LNM. Two studies [20, 21] reported the number of LNM cases between high and low expression of HULC for 404 cancer patients. Because of severe heterogeneity with 2 studies (I 2 = 80%, P Q = 0.03), the random-effects model was used to calculate the pooled effect. The LNM rate was significantly elevated in patients with high versus HULC expression, with pooled OR = 4.83 (95% CI 1.59-14.63) (Fig 2a) . Association between HULC and DM. Three studies [20, 19, 18] reported the number of DM cases for the 2 groups of HULC expression, for 216 patients. With no severe heterogeneity among the studies (I 2 = 0%, P Q = 0.93), the fixed-effects model was used in the pooled analysis.
Risk of developing DM was increased with high versus low HULC expression (OR = 5.44, 95% CI 2.33-12.74) (Fig 2b) .
Association between HULC and prognosis
Association between HULC and OS. All included studies showed data for OS by HULC level for 966 cancer patients. Because of significant heterogeneity (I 2 = 77%, P Q <0.0001), the random-effects model was used. The pooled HR of OS was 1.76 (95% CI 1.11-2.79, P = 0.02) for high versus low HULC expression (Fig 3) , so high HULC expression decreased the OS time. Because the detected specimens were from cancer tissues and serum of patients, we also calculated the pooled HR for OS by specimen type. For studies of cancer tissue [19, 11, 21, 13, 18, 23, 17] , the pooled HR for OS was 1.72 (95% CI 1.01-2.92) under the random-effects model (I 2 = 80%, P Q <0.0001) (S1a Fig) and for studies of serum, was 2.01 (95% CI 1.04-4.64)
under the fixed-effects model (I 2 = 0%, P Q = 0.85) [20, 22] 
(S1b Fig).
Association between HULC and recurrence. Two studies [19, 21] reported the number of recurrences by expression of HULC for 342 patients. The 2 studies showed no significant heterogeneity (I 2 = 0%, P Q = 0.50), and a fixed-effects model was used. High HULC expression significantly increased the recurrence of cancer in patients (OR = 6.68, 95% CI 2.77-16.13) (Fig 4) . 
Sensitivity analysis
Sensitivity analysis was conducted for the association between HULC and OS. Each study was deleted in turn to examine the influence of the removed data on the overall HR ( Table 3 ). The exclusion of each study did not change the significant result, which suggested that the pooled result was robust and not from random effects. Furthermore, when the results of Yang Z, et al. were removed from the pooled analysis, the degree of significance increased and no severe heterogeneity was found among the other studies (I 2 = 0%, P Q = 0.88). It implied that the heterogeneity among studies resulted from the Yang Z, et al. study and the effect of HULC on OS differed among ethnic groups. Therefore, we pooled the effect of HULC on OS for Chinese 
Publication bias
Publication bias for the association between HULC and OS was checked by a Begg's funnel plot under the random-effects model (Fig 5) . Although the funnel plot seemed asymmetric, Begg's test showed no significant rank correlation with Kendall score (Z = 0.31, Pr> |z| = 0.754). Given this result, we performed Egger's test where evidence of significance publication bias was found (r = 1.90, 95% CI 1.01-2.79, P>|t| = 0.001). Therefore, studies finding high HULC expression associated with short OS might more frequently be published and included in the meta-analysis (S3 Fig). We performed trim and fill analysis to adjust the final effect; the 
Discussion
This current study aimed to assess the pooled effect of HULC expression on prognosis with cancer. High HULC expression was associated with increased cancer metastasis and decreased survival time. Furthermore, high HULC expression was an important factor in cancer recurrence. Because most of the studies were from China, the level of HULC can be useful for predicting prognosis for Chinese cancer patients and providing a target for therapy. HULC, originally found in hepatocellular carcinoma, has been found highly expressed in tumor tissues in different cancer as compared with paired corresponding non-cancerous tissues. Moreover, silencing HULC could significantly inhibit tumor cell proliferation, migration and invasive capability in vitro. Overexpressing HULC could enhance cancer cell proliferation, migration and invasion. [24, 25, 18] Preliminary research in the mechanism of HULC found that it could co-purify with ribosomes in the cytoplasm and play a role in post-transcriptional modulation of gene expression. [26, 27] Research has identified that HULC could perturb the circadian rhythm of cancer cells and contribute to the epithelial-to-mesenchymal transition (EMT), required for cancer metastasis and invasion. [19, 27, 25, 24] In addition, HULC knockdown could enhance cisplatin-induced apoptosis in cancer cells. Therefore, HULC is an oncogenic lncRNA and participates in tumor development and progression.
In our meta-analysis, 4 studies reported the association between HULC expression and metastasis and 9 the effect of HULC on survival. The risk of occurrence of LNM and DM was increased with high versus low HULC expression and the OS time was shorter. Although subgroups of survival, such as EFS, DFS and PFS, could not be pooled because of too few studies, high HULC expression was still significantly associated with cancer recurrence. In addition, we examined the results for HULC tested in serum and tissue [20, 22, 28] and found OS time decreased with high versus low serum level of HULC. Because the effect of serum HULC level on OS was similar to that of tissue content, serum HULC level might be used for surveying the effect of therapy for cancer patients.
Some meta-analyses focused on the association of lncRNAs such as MALAT-1 [29] , AFA-P1-AS1 [30] , H19 [31] , and PVT1 [32] and metastasis as well as prognosis with cancer; all analyzed only the lncRNAs detected in cancer tissues. To search for an applicable biomarker for therapy, we focused on the association of tissue HULC content on metastasis and prognosis as well as serum HULC content and prognosis. To our best knowledge, this is the first meta-analysis of the effect of HULC on outcomes for cancer patients.
Our study contains some limitations. First, the types of cancer and samples of patients in the included studies were few and publication bias existed. Second, because of heterogeneity of ethnic groups in the included studies and most studies from China, the results may represent Chinese cancer patients only. Third, because of the nature of the meta-analysis using aggregated group data, the confounding factors could not be controlled. Fourth, because there were few studies on expression of HULC with LNM, DM recurrence, and OS in subgroup, significance of some of our findings was limited by the low precision as indicated by the wide confidence intervals. Therefore, larger-scale, multicenter, and high-quality studies are needed to confirm our findings.
Conclusions
This meta-analysis is the first to demonstrate that high expression of the long noncoding RNA HULC is related to poor prognosis for cancer patients. The expression of HULC, especially tested in serum, might be a biomarker for surveillance of prognosis for cancer patients, especially in China. 
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